Chris Boshoff, M.D., Ph.D., FMedSci, is the Head and Vice President for Early Development, Translational and Immuno-Oncology at Pfizer where he directs the strategies for early cancer drug development, and precision and immuno-oncology. Dr. Boshoff obtained his PhD from the Institute of Cancer Research in London and trained as a medical oncologist at the Royal Marsden and Royal Free Hospitals in London. Before joining Pfizer in 2013, he was the Director of the University College London (UCL) Cancer Institute (2007-2013). He was appointed Adjunct Professor at Yale University in 2014, and has published more than 150 original articles covering cancer biology, tumor virology, and experimental cancer medicine.